Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda(University of Maryland, Baltimore), Anders Österborg(Karolinska University Hospital), Stephan Stilgenbauer(Universität Ulm), Magdalena Piotrowska(The University of Texas System), Thomas J. Kipps(University of California San Diego), Charlotte Russell(The University of Texas System), Joris Wilms(The University of Texas System), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Jiřı́ Mayer(Masaryk University), Nedjad Losic(The University of Texas System), Martin J.S. Dyer(University of Leicester), Tadeusz Robak(Medical University of Lodz), Marek Trněný(Charles University), Tomáš Kozák(The University of Texas System), Geoffrey Chan(The University of Texas System), Cathy Williams(The University of Texas System), Randy Davis(The University of Texas System), Andrzej Hellmann(Gdańsk Medical University), Richard R. Furman(Cornell University)
Cited by 587
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k